NASDAQ:CCXI ChemoCentryx (CCXI) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$51.99▼$51.9950-Day Range$51.66▼$51.9952-Week Range$14.95▼$52.00Volume113 shsAverage Volume1.68 million shsMarket Capitalization$3.71 billionP/E RatioN/ADividend YieldN/APrice Target$59.25 ProfileProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability ChemoCentryx MarketRank™ ForecastAnalyst RatingHold2.20 Rating ScoreUpside/Downside14.0% Upside$59.25 Price TargetShort InterestN/ADividend StrengthN/ASustainability-1.75Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.81) to ($0.75) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.50 out of 5 starsMedical Sector933rd out of 1,009 stocksPharmaceutical Preparations Industry467th out of 494 stocks 2.1 Analyst's Opinion Consensus RatingChemoCentryx has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $59.25, ChemoCentryx has a forecasted upside of 14.0% from its current price of $51.99.Amount of Analyst CoverageChemoCentryx has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for CCXI. Previous Next 0.0 Dividend Strength Dividend YieldChemoCentryx does not currently pay a dividend.Dividend GrowthChemoCentryx does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreChemoCentryx has received a 62.39% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Immunosuppressants (L04)", "Clinical research services for physiological diseases ", and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for ChemoCentryx is -1.75. Previous Next 0.0 News and Social Media Coverage MarketBeat FollowsOnly 1 people have added ChemoCentryx to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ChemoCentryx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.30% of the stock of ChemoCentryx is held by insiders.Percentage Held by Institutions81.09% of the stock of ChemoCentryx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ChemoCentryx are expected to grow in the coming year, from ($1.81) to ($0.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ChemoCentryx is -27.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ChemoCentryx is -27.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChemoCentryx has a P/B Ratio of 12.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ChemoCentryx (NASDAQ:CCXI) StockChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.Read More Receive CCXI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ChemoCentryx and its competitors with MarketBeat's FREE daily newsletter. Email Address CCXI Stock News HeadlinesOctober 20, 2022 | prnewswire.comAMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX - PR NewswireOctober 20, 2022 | finance.yahoo.comAMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYXMay 30, 2023 | Edge On The Street (Ad)Is Graphite the New Lithium?Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.October 17, 2022 | finance.yahoo.comChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings - Yahoo FinanceOctober 17, 2022 | finance.yahoo.comChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual MeetingsOctober 15, 2022 | nasdaq.comChemoCentryx Inc Shares Close in on 52-Week High - Market Mover - NasdaqOctober 7, 2022 | nasdaq.comChemoCentryx Inc Shares Approach 52-Week High - Market Mover - NasdaqOctober 6, 2022 | nasdaq.comIs ChemoCentryx (CCXI) Stock Outpacing Its Medical Peers This Year? - NasdaqMay 30, 2023 | Edge On The Street (Ad)Is Graphite the New Lithium?Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.October 6, 2022 | finance.yahoo.comIs ChemoCentryx (CCXI) Stock Outpacing Its Medical Peers This Year?October 5, 2022 | globenewswire.comChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting - GlobeNewswireOctober 5, 2022 | finance.yahoo.comChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual MeetingSeptember 30, 2022 | fool.comChemoCentryx (NASDAQ: CCXI)September 24, 2022 | thestreet.comBiotech Valuations Remain In a Slump - TheStreetSeptember 19, 2022 | gurufocus.comAmgen CEO Sees Tougher Sleddin - GuruFocus.comSeptember 19, 2022 | investors.comThese 10 Biotech Stocks Would Have Netted You $10000 More This Year - Investor's Business DailySeptember 15, 2022 | nasdaq.comSPDR S&P Biotech ETF Experiences Big Inflow - NasdaqSeptember 14, 2022 | seekingalpha.comAmgen (AMGN): Growing Doubts About The Future - Seeking AlphaSeptember 13, 2022 | stockhouse.com2022-09-13 | NDAQ:CCXI | Press Release | ChemoCentryx Inc. - StockhouseSeptember 13, 2022 | businesswire.comINVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCentryx, Inc.'s Directors and Officers for Breach of Fiduciary Duties – CCXI - Business WireSeptember 13, 2022 | benzinga.comChemoCentryx (NASDAQ:CCXI) – INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCent - BenzingaSeptember 13, 2022 | seekingalpha.comAmgen Stock Is Looking Interesting On The Dip (NASDAQ:AMGN) - Seeking AlphaSeptember 7, 2022 | nasdaq.comWhy Is ChemoCentryx (CCXI) Up 1.4% Since Last Earnings Report? - NasdaqSeptember 7, 2022 | finance.yahoo.comWhy Is ChemoCentryx (CCXI) Up 1.4% Since Last Earnings Report?September 5, 2022 | reuters.comCCXI.N - ChemoCentryx Inc | Stock Price & Latest News | ReutersSeptember 4, 2022 | reuters.comCCXI.O - ChemoCentryx Inc | Stock Price & Latest News | ReutersSeptember 1, 2022 | benzinga.comChemocentryx (CCXI) – ChemoCentryx's Return On Capital Employed Insights - BenzingaSee More Headlines Receive CCXI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ChemoCentryx and its competitors with MarketBeat's FREE daily newsletter. Email Address CCXI Company Calendar Last Earnings11/08/2021Today5/30/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:CCXI CUSIP16383L10 CIK1340652 Webwww.chemocentryx.com Phone(650) 210-2900Fax650-210-2910Employees178Year FoundedN/APrice Target and Rating Average Stock Price Forecast$59.25 High Stock Price Forecast$81.00 Low Stock Price Forecast$52.00 Forecasted Upside/Downside+14.0%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-131,760,000.00 Net Margins-357.01% Pretax Margin-357.01% Return on Equity-48.52% Return on Assets-30.59% Debt Debt-to-Equity Ratio0.02 Current Ratio4.54 Quick Ratio4.47 Sales & Book Value Annual Sales$32.22 million Price / Sales115.14 Cash FlowN/A Price / Cash FlowN/A Book Value$4.09 per share Price / Book12.71Miscellaneous Outstanding Shares71,356,000Free Float65,433,000Market Cap$3.71 billion OptionableOptionable Beta1.22 Key ExecutivesDr. Thomas J. Schall Ph.D. (Age 63)Founder, Pres, CEO & Chairman Comp: $1.21MMs. Susan M. Kanaya (Age 59)Exec. VP, Chief Financial & Admin. Officer, Sec. and Director Comp: $845.04kMr. Tausif Butt (Age 56)Exec. VP & COO Comp: $1.01MDr. Rita I. Jain M.D. (Age 59)Exec. VP, Chief Medical Officer & Exec. Employee Director Comp: $670.7kDr. Markus J. Cappel Ph.D. (Age 61)Chief Bus. Officer & Treasurer Comp: $643.58kMs. Yi Ching Yau (Age 46)Sr. VP of Fin. & Principal Accounting Officer Mr. William S. SlatteryVP of Investor Relations & Corp. CommunicationsMs. Kari E. LeetchSr. VP of HRDr. Sangita Ghosh Ph.D.Sr. VP of Technical OperationsMore ExecutivesKey CompetitorsAmicus TherapeuticsNASDAQ:FOLDImmunoGenNASDAQ:IMGNAlkermesNASDAQ:ALKSMadrigal PharmaceuticalsNASDAQ:MDGLIronwood PharmaceuticalsNASDAQ:IRWDView All CompetitorsInsidersSusan M KanayaSold 19,898 sharesTotal: $1.01 M ($50.95/share)Thomas J SchallSold 130,000 sharesTotal: $6.53 M ($50.24/share)Susan M KanayaSold 46,298 sharesTotal: $2.32 M ($50.17/share)Markus J CappelSold 7,564 sharesTotal: $379,864.08 ($50.22/share)James L TyreeSold 10,000 sharesTotal: $502,200.00 ($50.22/share)View All Insider Transactions CCXI Stock - Frequently Asked Questions Should I buy or sell ChemoCentryx stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CCXI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CCXI, but not buy additional shares or sell existing shares. View CCXI analyst ratings or view top-rated stocks. What is ChemoCentryx's stock price forecast for 2023? 5 Wall Street research analysts have issued 1 year target prices for ChemoCentryx's shares. Their CCXI share price forecasts range from $52.00 to $81.00. On average, they expect the company's stock price to reach $59.25 in the next twelve months. This suggests a possible upside of 14.0% from the stock's current price. View analysts price targets for CCXI or view top-rated stocks among Wall Street analysts. How were ChemoCentryx's earnings last quarter? ChemoCentryx, Inc. (NASDAQ:CCXI) issued its quarterly earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.13. The biopharmaceutical company had revenue of $17.74 million for the quarter, compared to analysts' expectations of $14.70 million. ChemoCentryx had a negative trailing twelve-month return on equity of 48.52% and a negative net margin of 357.01%. During the same period in the prior year, the firm posted ($0.35) EPS. What is Thomas J. Schall's approval rating as ChemoCentryx's CEO? 21 employees have rated ChemoCentryx Chief Executive Officer Thomas J. Schall on Glassdoor.com. Thomas J. Schall has an approval rating of 58% among the company's employees. This puts Thomas J. Schall in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 44.0% of employees surveyed would recommend working at ChemoCentryx to a friend. What other stocks do shareholders of ChemoCentryx own? Based on aggregate information from My MarketBeat watchlists, some companies that other ChemoCentryx investors own include Exelixis (EXEL), Energy Transfer (ET), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Amicus Therapeutics (FOLD), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Advanced Micro Devices (AMD) and Arrowhead Pharmaceuticals (ARWR). What is ChemoCentryx's stock symbol? ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI." What is ChemoCentryx's stock price today? One share of CCXI stock can currently be purchased for approximately $51.99. How much money does ChemoCentryx make? ChemoCentryx (NASDAQ:CCXI) has a market capitalization of $3.71 billion and generates $32.22 million in revenue each year. The biopharmaceutical company earns $-131,760,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis. How many employees does ChemoCentryx have? The company employs 178 workers across the globe. How can I contact ChemoCentryx? ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The official website for the company is www.chemocentryx.com. The biopharmaceutical company can be reached via phone at (650) 210-2900, via email at investor@chemocentryx.com, or via fax at 650-210-2910. This page (NASDAQ:CCXI) was last updated on 5/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ChemoCentryx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.